Robert E. Landry - 31 Jan 2024 Form 4 Insider Report for REGENERON PHARMACEUTICALS, INC. (REGN)

Role
EVP Finance CFO
Signature
/s/**Robert E. Landry
Issuer symbol
REGN
Transactions as of
31 Jan 2024
Net transactions value
-$117,272
Form type
4
Filing time
02 Feb 2024, 16:02:11 UTC
Previous filing
25 Jan 2024
Next filing
06 Feb 2024
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction REGN Common Stock Options Exercise $151,592 +400 +1.7% $378.98 23,856 31 Jan 2024 Direct
transaction REGN Common Stock Tax liability $268,864 -282 -1.2% $953.42 23,574 31 Jan 2024 Direct
holding REGN Common Stock 270 31 Jan 2024 By 401(k) Plan

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction REGN Non-Qualified Stock Option (right to buy) Options Exercise $0 -400 -3.2% $0.000000 12,187 31 Jan 2024 Common Stock 400 $378.98 Direct F1
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The stock option award vests in four equal annual installments, commencing one year after the date of grant.